
Online Resource 2: Module Slides





History:


 44 year old male with no significant past medical history had persistent headaches which lasted several weeks. The patient went to an acute care clinic and was given prednisone and antibiotics for a presumed sinus infection. The pressure associated with his headaches improved for several days while he was on the prednisone. However, after he stopped prednisone, his headaches returned. The patient presented to the emergency room because of worsening severe headaches.

• What imaging test is the appropriate next step?









CORRECT!

Correct answer: MRI head without and with contrast


• Explanation:

8

Xplanation: For the workup of a potential mass or abscess, and MRI of the head without and with contrast is the best study. If the patient cannot get contrast, a non-contrast MRI can still be helpful. CT angiogram is best for evaluating the arteries and is not the next step in the workup of a mass lesion.





Click here to continue







10














Clinical Course


- CT of the chest, abdomen, and pelvis did not show any evidence of a primary malignancy
- The patient was taken to the OR and gross total resection of the rim enhancing mass was performed
- Pathology showed glioblastoma, IDH 1 wild type, MGMT promoter un-methylated

Click here to learn more about IDH 1 and MGMT status

• An MRI was obtained 24 hours after the resection

Click here to see the post-op MRI





IDH1 and MGMT


• IDH wildtype vs mutant:

Methylated: More likely to have pseudoprogression
Unmethylated: Less likely to have pseudoprogression


Click here to see the post-op MRI

Wildtype: started as glioblastomaMutant: arose from a lower grade glioma


• MGMT Methylation:



24 hour Post-operative Imaging



20



21

Clinical Course

- The post-operative scan showed no evidence of residual enhancing tumor at the site of resection
- The patient was then treated with standard chemotherapy and radiation therapy
- What is the name of the standard first line chemotherapy used to treat glioblastoma?

Click here to see the answer

22

Clinical Course


- The post-operative scan showed no evidence of residual enhancing tumor at the site of resection
- The patient was then treated with standard chemotherapy and radiation therapy
- What is the name of the standard first line chemotherapy used to treat glioblastoma?
 - Answer: Temozolomide (also called TMZ or Temodar)

Click here to continue

Clinical Course

- After completing 3 months of chemo-radiation a follow-up scan was obtained
- What are 3 reasons you may have increasing enhancement on the first post-treatment follow-up MRI in glioblastoma cases?







Pseudoprogression


- Occurs in patients treated with temozolomide and radiation and also in patients on immunotherapy
- In TMZ/rad pseudoprogression occurs in a 3 month period starting at the END of radiation
 For this reason the end date of radiation should go in the history section of every GBM report
- On imaging, pseudoprogression is increasing enhancement around the surgical cavity that mimics tumor progression.
- Some techniques such as perfusion and PET/CT can favor pseudoprogression over true progression (low perfusion, low metabolic activity on PET)
- The gold standard for making the diagnosis is a short interval (4 week) follow up MRI showing the enhancement has decreased whereas tumor will increase


Click here to see the post-treatmen MRI


26













Clinical Course


- Several follow-up MRI's were obtained at 2-3 month intervals, all showing no disease progression
- 1 year after the initial resection the patient had a new finding on his brain MRI


Click here to see the MRI



















Radiation Necrosis


- Occurs in patients treated with radiation
- Tends to peak at around 18 months after radiation treatment (unlike pseudoprogression which occurs in the first 3 months after the <u>end</u> of radiation)
- Radiation necrosis causes tissue enhancement and can mimic tumor but tends to have low CBV on perfusion and low metabolic activity on PET/CT
- Over time radiation necrosis can increase, decrease, or stay the same (unlike pseudoprogression which improves over time)
- Radiation necrosis can occasionally cause symptoms and may require treatment
 Click here to continue







- The patient underwent a re-resection of the enhancing abnormality
- Pathology showed recurrent glioblastoma
- The patient had an MRI 24 hours after the re-resection

Click here to see the MRI









Clinical Course


- In addition to more radiation and temozolomide the patient was started on bevacizumab (Avastin)
- After 2 months, a follow-up MRI was obtained.











Pseudoresponse	S
Bevacizumab is an antiangiogenic chemotherapy	Thin
 It can cause constriction of vessels leading to a decrease in enhancement despite progression of non-enhancing tumor 	•
 The diagnosis is made when a patient being treated with bevacizumab has improved enhancement but worsening FLAIR and/or diffusion abnormalities 	· · ·
Click here to continue	•

Summary

his case follows a patient with Glioblastoma. Concepts that are highlighted in this module clude: Initial diagnosis and differential diagnosis of brain mass

Click here to continue

- Relevant genetic markers in GBM
- What to look for on immediate post operative images
- What to look for on follow-up post treatment scans The typical chemotherapies used for GBM RANO criteria for characterization of GBM on follow-up imaging
- True progression
- Pseudoprogression
- seudoresponse

Radiation necrosis